91 results about "Kidney fibrosis" patented technology

The invention belongs to the technical field of traditional Chinese medicine sustained-release preparations, in particular to a water-soluble effective component containing centella asiatica for treating trauma, surgical trauma, burns, keloids and scleroderma, antidepressant and treating liver and kidney fibrosis. Centella glycosides) traditional Chinese medicine slow-release preparation and preparation method thereof. The invention adopts the modern preparation technology to compress the traditional Chinese medicine slow-release preparation with solid medicine, skeleton-type auxiliary materials and other excipients. The solid drug refers to the total glycosides of the water-soluble extract of the traditional Chinese medicine Centella asiatica. The total glycosides contain madecassoside and centella asiatica. The total glycosides content in the extract should not be less than 60%. Skeleton-type excipients mainly refer to hydroxypropyl methylcellulose. By adjusting the amount of excipients in the prescription, the release rate of asiaticoside can be controlled, so as to stabilize the blood concentration of the drug, reduce the frequency of medication, and facilitate the use of patients.

Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.

The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to O-(tetrahydropyrrolyl)ethyl derivatives of cleistanone, a preparation method and an application thereof in the preparation of drugs for preventing or treating renal fibrosis. The present invention synthesizes a new O-(tetrahydropyrrolyl) ethyl derivative of Cleistanone, and discloses its preparation method. Pharmacological experiments show that the O-(tetrahydropyrrolyl)ethyl derivatives of Cleistanone of the present invention have the effect of preventing or treating renal fibrosis, and have the value of developing drugs for preventing or treating renal fibrosis.

The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with fibrosis. In certain embodiments, such compounds are used to treat one or more symptoms associated with renal fibrosis.